The ZooMAb® recombinant antibodies platform represents an entirely new generation of recombinant monoclonal antibodies that offer the superior specificity and affinity of a monoclonal and polyclonal combined with the flexibility of a recombinant for a wider selection of targets, formats, and species.
COVID-19 Support & Resources
At Merck and GSC, we are committed to providing researchers with the required reagents and technical support during the COVID-19 pandemic. Explore our offering of ZooMAb recombinant monoclonal antibodies that are suitable for SARS-CoV-2 research.
Merck’s scientists have designed ZooMAb recombinant monoclonal antibodies against various SARS-CoV-1/2 targets. ZooMAb antibodies are all recombinantly produced, lyophilized, free of animal components, and offer the highest reproducibility to ensure optimal performance now and whenever you need them.
Featured SARS-CoV-1/2 ZooMAb® Products
Providing highly cited primary and secondary antibodies, we have you covered for all your ELISA, western blot, immunohistochemistry or other assay needs. Use the Antibody Explorer search tool to view and compare our antibodies from brands you know and trust, including Sigma-Aldrich, Millipore, Upstate, Chemicon, and Calbiochem.
